|
1
|
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
|
J Natl Cancer Inst
|
2005
|
6.03
|
|
2
|
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
|
J Natl Cancer Inst
|
2003
|
3.08
|
|
3
|
A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.
|
J Natl Cancer Inst
|
2002
|
1.83
|
|
4
|
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.82
|
|
5
|
Viral load of human papillomavirus and risk of CIN3 or cervical cancer.
|
Lancet
|
2002
|
1.78
|
|
6
|
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.
|
J Clin Oncol
|
2012
|
1.78
|
|
7
|
Diagnoses and outcomes in cervical cancer screening: a population-based study.
|
Am J Obstet Gynecol
|
2004
|
1.64
|
|
8
|
The health care costs of cervical human papillomavirus--related disease.
|
Am J Obstet Gynecol
|
2004
|
1.39
|
|
9
|
Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.
|
J Clin Oncol
|
2010
|
1.37
|
|
10
|
Abnormal outcomes following cervical cancer screening: event duration and health utility loss.
|
Med Decis Making
|
2007
|
1.28
|
|
11
|
Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions.
|
J Clin Microbiol
|
2007
|
1.22
|
|
12
|
Pap screening in a U.S. health plan.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
1.22
|
|
13
|
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.
|
J Clin Microbiol
|
2003
|
1.05
|
|
14
|
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.
|
Cancer Res
|
2008
|
1.05
|
|
15
|
Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.
|
Cancer
|
2002
|
1.03
|
|
16
|
Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies.
|
Cancer
|
2008
|
0.98
|
|
17
|
Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.97
|
|
18
|
Human papillomavirus prevalence in women who have and have not undergone hysterectomies.
|
J Infect Dis
|
2006
|
0.96
|
|
19
|
Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification.
|
Int J Gynecol Pathol
|
2008
|
0.95
|
|
20
|
Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study.
|
Mutat Res
|
2007
|
0.90
|
|
21
|
Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.
|
Int J Cancer
|
2012
|
0.82
|
|
22
|
Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201].
|
Health Policy
|
2005
|
0.76
|